Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.

SG&A Expenses: Zoetis vs. Agios from 2014 to 2023

__timestampAgios Pharmaceuticals, Inc.Zoetis Inc.
Wednesday, January 1, 2014191200001643000000
Thursday, January 1, 2015359920001532000000
Friday, January 1, 2016507140001364000000
Sunday, January 1, 2017711240001334000000
Monday, January 1, 20181141450001484000000
Tuesday, January 1, 20191320340001638000000
Wednesday, January 1, 20201490700001726000000
Friday, January 1, 20211214450002001000000
Saturday, January 1, 20221216730002009000000
Sunday, January 1, 20231199030002151000000
Monday, January 1, 20241567840002318000000
Loading chart...

Cracking the code

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, operational efficiency is key to success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Agios Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Zoetis Inc. consistently outpaced Agios Pharmaceuticals in SG&A spending, reflecting its larger scale and broader market reach. In 2023, Zoetis's SG&A expenses were approximately 18 times higher than those of Agios, highlighting its expansive operational framework. Interestingly, while Zoetis's expenses grew steadily, Agios saw a more volatile trend, with a peak in 2020. This could indicate strategic shifts or market challenges faced by Agios. Understanding these trends provides valuable insights into each company's operational strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025